Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company DecImmune Therapeutics Inc.
DescriptionA humanized mAb which inhibits IgM binding and blocks N2-driven inflammatory cascade
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cardiovascular (unspecified)
Indication DetailsTreat vascular inflammatory diseases
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today